REMARKS

Applicants herein amends claims 29, 31, 34, 57, 59 and 60. The subject matter of the new claims is fully supported by the specification as filed. No new matter is added by these amendments. Applicants believe pending claims 22-69 define over the prior art of record and are in proper form for allowance. Applicants respectfully request allowance of claims 22-69.

Respectfully submitted,

Bernard G. Pike

Registration No. 46,993

Kirkpatrick & Lockhart LLP Henry W. Oliver Building 535 Smithfield Street Pittsburgh, PA 15222-2312

Phone:

(412) 355-8620

Fax:

(412) 355-6501

Version of the Specification Showing Amendments Made

This application is a continuation application claiming priority under 35 U.S.C. § 120 from Application Serial No. 09/328,329 which issued into U.S. Patent No. 6,377,847 on April 23, 2002, that is a continuation-in-part of Application No. 08/533,979 filed September-29_26, 1995, now abandoned, which is a continuation-in-part of Application No. 08/129,222 filed September 30, 1993, now abandoned.

Version of the Claims Showing Amendments Made

- 29. (Once Amended) The iontophoretic drug delivery device of claim 28, wherein the concentration of glycerin is up to 10 wt. %, the concentration of sodium metabisulfite is up to 0.05 wt. %, the concentration of EDTA is up to 0.01 wt. %.
- 31. (Once Amended) The iontophoretic drug delivery device of claim 24, wherein the concentration of epinephrine, as measured in weight % of the total weight of the reservoir, is about 0.1 wt. % and the concentration of lidocaine is about 10 wt. %.
- 34. (Once Amended) The iontophoretic drug delivery device of claim 33, wherein the one to three return electrodes have a total surface area between 1 to 5 cm² and wherein the- working electrode has a surface area between 2 to 10 cm².
- 57. (Once Amended) The iontophoretic drug delivery device of claim 56, wherein the lidocaine is present up to 10 wt. % based on the total-with weight of the reservoir.
- 59. (Once Amended) The iontophoretic drug delivery device of claim 58, wherein the concentration of glycerin is up to 10 wt. %, the concentration of sodium metabisulfite is <u>up</u> to 0.05 wt. %, the concentration of EDTA is up to 0.01 wt. %, all- based on the total-with weight of the reservoir.
- 60. (Once Amended) The iontophoretic drug delivery device of claim 54, wherein the concentration of epinephrine, as measured in weight % of the total

weight of the reservoir, is about 0.1 wt. % and the concentration of lidocaine is about 10 wt. %, all- based on the total-with weight of the reservoir.

63. (Once Amended) The iontophoretic drug delivery device of claim 62, wherein the return electrodes have a total surface area from 1 to 5 cm² and wherein the- working electrode has a surface area from 2 to 10 cm².